ClinicalTrials.gg
CompletedNCT02636699PEPITESUpdated Jun 18, 2025Results posted

Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

A Phase 3 interventional study of Viaskin Peanut 250mcg and Placebo in Peanut Allergy, sponsored by DBV Technologies. Completed at 31 sites in 5 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by DBV Technologies · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
4 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing palforzia in Peanut Hypersensitivity — none open to participants now, 3 under way, 2 of them phase 3. Palforzia · Peanut Hypersensitivity.

Enrollment
2nd of 10
500 · median 105
Started
2015
the only one that year
Phase 3
4 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
5 of 10
DBV Technologies

Among the 10 studies testing palforzia in Peanut Hypersensitivity, this one is the 2nd largest by enrollment, is the only one that started in 2015, is one of 4 in phase 3, and was the 4th registered.

Peanut Hypersensitivity

166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.

Browse Peanut Hypersensitivity studies →

Open to participants now

None of the 10 studies testing palforzia in Peanut Hypersensitivity is open now. The open studies under Peanut Hypersensitivity, anywhere →

About palforzia

Palforzia: first FDA approval 2020 (Palforzia). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 4 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing palforzia in Peanut Hypersensitivity as a file.
02

Study summary

The PEPITES study evaluates the efficacy and safety of Viaskin Peanut 250 µg peanut protein to induce desensitization to peanut in peanut-allergic children 4 through 11 years of age after a 12-month treatment by epicutaneous immunotherapy (EPIT).

Read the detailed description

This is a 12-month, Phase III, double-blind, placebo-controlled, randomized study to assess the efficacy and safety of Viaskin Peanut, dosed at 250µg peanut protein (per patch) in peanut-allergic children from 4 through 11 years of age.

The overall maximum study duration for each subject is approximately 61 weeks (6-week screening period, 12-month treatment period and 2-week follow-up period).

During the screening period, subjects will undergo a first screening visit and an entry double-blind, placebo-controlled food challenge (DBPCFC) to peanut to confirm their allergy and their entry peanut eliciting dose (ED). The starting dose of the challenge will be 1 mg peanut protein and will escalate up to a highest dose of 300mg peanut protein. Subjects who react at or below the dose of 300mg peanut protein are considered eligible.

Randomization of eligible subjects will occur in a 2:1 ratio to Viaskin Peanut dosed at 250µg peanut protein (active treatment) or placebo. Subjects will be stratified at randomization by their entry/screening DBPCFC ED in 1 of the following 2 strata and by study center:

  • Stratum 1: children with a screening ED of 1mg, 3mg or 10mg;
  • Stratum 2: children with a screening ED of 30mg, 100mg or 300mg.

Subjects will apply a Viaskin patch containing either peanut protein or placebo daily for a period of 12 months. At Month 12, a post-treatment DBPCFC to peanut will be performed, with a starting dose of 1 mg peanut protein with escalation up to a highest dose of 2,000 mg peanut protein. This evaluation will help determine the primary efficacy endpoint of this pivotal study.

03

Conditions studied

  • Peanut Allergy
04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Male or female children aged 4 through 11 years;
  2. Physician-diagnosis of peanut allergy or children with a well documented medical history of IgE-mediated symptoms after ingestion of peanut and currently following a strict peanut-free diet, but without a physician diagnosis;
  3. Peanut-specific IgE level (ImmunoCAP system) >0.7 kU/L;
  4. Positive peanut skin prick test (SPT) with a largest wheal diameter:

    • ≥6 mm for children 4 through 5 years of age at Visit 1,
    • ≥8 mm for children 6 years and above at Visit 1;
  5. Positive DBPCFC at ≤300 mg peanut protein.

Main Exclusion Criteria:

  1. History of severe anaphylaxis to peanut with any of the following symptoms: hypotension, hypoxia, neurological compromise (collapse, loss of consciousness or incontinence);
  2. Generalized dermatologic disease
  3. Diagnosis of mast cell disorders, including mastocytosis or uricaria pigmentosa as well as hereditary or idiopathic angioedema;
  4. Diagnosis of asthma that fulfills any of the following criteria:

    • Uncontrolled persistent asthma as defined by National Asthma Education and Prevention Program Asthma guidelines 2007 or by Global Initiative for Asthma guidelines 2015,
    • Asthma treated with either a high daily high dose of inhaled or with a combination therapy of a medium or high daily dose of inhaled corticosteroid with a long acting inhaled β2 agonist or with a combination therapy of a high daily dose of inhaled corticosteroid with a long acting inhaled β2 agonist. Asthmatic subjects treated with a medium daily dose of inhaled corticosteroids are eligible. Intermittent asthmatic subjects who require intermittent use of inhaled corticosteroids for rescue are also eligible,
    • Two or more systemic corticosteroid courses for asthma in the past year or 1 oral corticosteroid course for asthma within 3 months prior to Visit 1, or during screening period,
    • Prior intubation/mechanical ventilation for asthma within 1 year prior to Visit 1, or during screening;
  5. Receiving β-blocking agents, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers or tricyclic antidepressant therapy;
  6. Received anti-tumor necrosis factor drugs or anti-IgE drugs (such as omalizumab) or any biologic immunomodulatory therapy within 1 year prior to Visit 1, during screening period or during study participation;
  7. Use of systemic long-acting corticosteroids within 12 weeks prior to Visit 1 and/or use of systemic short-acting corticosteroids within 4 weeks prior to Visit 1 or during screening;
  8. Prior or concomitant history of any immunotherapy to any food;
  9. Receiving or planning to receive any aeroallergen immunotherapy during their participation in the study. Aeroallergen immunotherapy must be discontinued at the time of Visit 1;
  10. Any disorder in which epinephrine is such as coronary artery disease, uncontrolled hypertension, or serious ventricular arrhythmias.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
500 participants (actual)

Study arms

  • Experimental
    Viaskin Peanut 250mcg

    One Viaskin epicutaneous delivery system (patch) containing 250 µg of peanut protein applied on the skin for 24 hours (±4 hours of allowance) daily for a period of 12 months.

    Biological: Viaskin Peanut 250mcg

  • Placebo comparator
    Placebo

    One Viaskin epicutaneous delivery system (patch) containing placebo applied on the skin for 24 hours (±4 hours of allowance) daily for a period of 12 months.

    Biological: Placebo

Interventions

  • Peanut extract cutaneous patch

    Also known as: DBV712

  • BiologicalPlacebo

    Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract

06

What researchers measure

Primary outcomes

  1. Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall Population

    The Double-Blind Placebo-Controlled Food Challenges (DBPCFCs) to determine Eliciting Dose (ED) were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of standardized blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if: * ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or * ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2). Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed in the overall population.

    Time frame: At Month 12

Secondary outcomes

  1. Difference in Percentages of Treatment Responders at Month 12; Analyzed in Each Screening Eliciting Dose (ED) Subgroup

    The Double-Blind Placebo-Controlled Food Challenges (DBPCFCs) to determine Eliciting Dose (ED) were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if: * ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or * ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2). Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented below. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed for each separate screening ED subgroup.

    Time frame: At Month 12

  2. Cumulative Reactive Dose (CRD) of Peanut Protein at Baseline and Month 12

    The CRD was calculated as the sum of all doses given (including any repeated and partial doses). The median CRD of peanut protein at baseline and Month 12 is presented. Analysis was performed using the modified baseline observation carried forward method to impute missing data at Month 12.

    Time frame: Baseline and Month 12

Other outcomes

  1. Relative Change From Baseline in Peanut-specific Immunoglobulin E (IgE) Over Time

    Venous blood samples were drawn to assess peanut-specific IgE levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgE levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.

    Time frame: Baseline and Months 3, 6 and 12

  2. Relative Changes From Baseline in Peanut-specific Immunoglobulin G4 Subtype (IgG4) Over Time

    Venous blood samples were drawn to assess peanut-specific IgG4 levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgG4 levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.

    Time frame: Baseline and Months 3, 6 and 12

07

Results

Posted Oct 15, 2021

Participant flow

This Phase III study was conducted in participants aged 4 to 11 years old with peanut allergy at 31 active centers in Australia, Canada, Germany, Ireland and USA. Participants were randomized in a 2:1 ratio to receive DBV712 250 micrograms (μg) (Viaskin® Peanut 250 μg) or placebo.

Screening Period
Participant flow — Screening Period
MilestoneDBV712 250 μgPlaceboScreened
Started00500
Completed00356
Not completed00144
Withdrew: Inclusion/exclusion failure00117
Withdrew: Withdrawal by subject0023
Withdrew: Adverse event001
Withdrew: Other not specified003
Treatment and Follow-up Periods
Participant flow — Treatment and Follow-up Periods
MilestoneDBV712 250 μgPlaceboScreened
Started2381180
Completed2131070
Not completed25110
Withdrew: Adverse event400
Withdrew: Lost to follow-up330
Withdrew: Non-compliance with the investigational product (ip)200
Withdrew: Physician decision010
Withdrew: Withdrawal by subject1360
Withdrew: Other310

Outcome measures

PrimaryDifference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall Population

The Double-Blind Placebo-Controlled Food Challenges (DBPCFCs) to determine Eliciting Dose (ED) were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of standardized blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if: * ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or * ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2). Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed in the overall population.

Time frame:
At Month 12
Reported as:
Number · percentage of participants
Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall Population
percentage of participantsDBV712 250 μgPlacebo
Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall Population35.3 (29.5 to 41.6)13.6 (8.5 to 20.9)
Statistical analysis
  • DBV712 250 μg vs Placebo · Wald · p = <0.001 · Difference in response rates (%): 21.7 · 95% CI 12.4 to 29.8
SecondaryDifference in Percentages of Treatment Responders at Month 12; Analyzed in Each Screening Eliciting Dose (ED) Subgroup

The Double-Blind Placebo-Controlled Food Challenges (DBPCFCs) to determine Eliciting Dose (ED) were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if: * ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or * ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2). Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented below. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed for each separate screening ED subgroup.

Time frame:
At Month 12
Reported as:
Number · percentage of participants
Difference in Percentages of Treatment Responders at Month 12; Analyzed in Each Screening Eliciting Dose (ED) Subgroup
percentage of participantsDBV712 250 μgPlacebo
Screening ED subgroup 139.0 (25.7 to 54.3)20.0 (8.1 to 41.6)
Screening ED subgroup 234.5 (28.2 to 41.4)12.2 (7.1 to 20.2)
Statistical analysis
  • DBV712 250 μg vs Placebo · Wald · p = 0.105 · Difference in response rates (%): 19.0 · 95% CI -6.4 to 38.4
  • DBV712 250 μg vs Placebo · Wald · p = <0.001 · Difference in response rates (%): 22.3 · 95% CI 12.1 to 30.8
SecondaryCumulative Reactive Dose (CRD) of Peanut Protein at Baseline and Month 12

The CRD was calculated as the sum of all doses given (including any repeated and partial doses). The median CRD of peanut protein at baseline and Month 12 is presented. Analysis was performed using the modified baseline observation carried forward method to impute missing data at Month 12.

Time frame:
Baseline and Month 12
Reported as:
Median · mg
Cumulative Reactive Dose (CRD) of Peanut Protein at Baseline and Month 12
mgDBV712 250 μgPlacebo
Baseline144.0 (44.0 to 444.0)144.0 (44.0 to 444.0)
Month 12444.0 (144.0 to 1444.0)144.0 (44.0 to 444.0)
Statistical analysis
  • DBV712 250 μg vs Placebo · Wilcoxon rank-sum test · p = <0.001 · Difference in median crd: 297.0 · 95% CI 130.0 to 317.0
Other pre-specifiedRelative Change From Baseline in Peanut-specific Immunoglobulin E (IgE) Over Time

Venous blood samples were drawn to assess peanut-specific IgE levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgE levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.

Time frame:
Baseline and Months 3, 6 and 12
Reported as:
Median · Percent of change
Relative Change From Baseline in Peanut-specific Immunoglobulin E (IgE) Over Time
Percent of changeDBV712 250 μgPlacebo
Month 378.716 (26.557 to 174.588)16.964 (-12.591 to 48.802)
Month 639.716 (-3.676 to 109.690)4.605 (-26.380 to 30.352)
Month 122.858 (-24.739 to 61.058)-6.919 (-31.468 to 25.291)
Other pre-specifiedRelative Changes From Baseline in Peanut-specific Immunoglobulin G4 Subtype (IgG4) Over Time

Venous blood samples were drawn to assess peanut-specific IgG4 levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgG4 levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.

Time frame:
Baseline and Months 3, 6 and 12
Reported as:
Median · Percent of change
Relative Changes From Baseline in Peanut-specific Immunoglobulin G4 Subtype (IgG4) Over Time
Percent of changeDBV712 250 μgPlacebo
Month 3127.778 (55.660 to 259.615)14.286 (0.000 to 45.833)
Month 6258.491 (107.843 to 549.351)11.492 (-9.677 to 42.105)
Month 12513.487 (196.458 to 1105.235)10.496 (-10.108 to 33.333)

Adverse events

Collected over Screened arm: Adverse Events (AEs) collected from signing the informed consent up to the end of the screening period. DBV712 250µg and placebo arms: Treatment-Emergent Adverse Events (TEAEs) collected from Day 1, throughout the 53-week treatment period and additional 2-week follow-up period. Overall time frame of up to 55 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DBV712 250 μg0/238 (0%)10/238 (4.2%)222/238 (93.3%)
Placebo0/118 (0%)6/118 (5.1%)96/118 (81.4%)
Screened0/500 (0%)9/500 (1.8%)83/500 (16.6%)
Most frequent serious events
Most frequent serious events
EventDBV712 250 μgPlaceboScreened
Anaphylactic reactionImmune system disorders6/2383/1188/500
AppendicitisInfections and infestations1/2381/1180/500
Visual impairmentEye disorders0/2381/1180/500
Coeliac diseaseGastrointestinal disorders0/2381/1180/500
Food allergyImmune system disorders1/2380/1180/500
TonsillitisInfections and infestations1/2380/1180/500
Throat irritationRespiratory, thoracic and mediastinal disorders1/2380/1180/500
WheezingRespiratory, thoracic and mediastinal disorders1/2380/1180/500
Encephalitis influenzalInfections and infestations0/2380/1181/500
Most frequent other events
Showing 10 of 36
Most frequent other events
EventDBV712 250 μgPlaceboScreened
Application site pruritusGeneral disorders83/23814/1180/500
Upper respiratory tract infectionInfections and infestations73/23830/11816/500
Application site erythemaGeneral disorders67/23820/1180/500
CoughRespiratory, thoracic and mediastinal disorders52/23815/1183/500
PyrexiaGeneral disorders48/23822/1185/500
Viral upper respiratory tract infectionInfections and infestations42/23820/1188/500
HeadacheNervous system disorders39/23818/1185/500
Application site swellingGeneral disorders38/2382/1180/500
AsthmaRespiratory, thoracic and mediastinal disorders30/23816/1182/500
VomitingGastrointestinal disorders31/23810/1186/500

Baseline characteristics

The intent-to-treat (ITT) population was comprised of all participants who were randomized.

Age, Continuous
Age, Continuous(years)DBV712 250 μgPlaceboTotal
Mean7.4 ± 2.117.3 ± 2.307.3 ± 2.17
Age, Customized
Age, Customized(Participants)DBV712 250 μgPlaceboTotal
4 to 5 years553287
6 to 11 years18386269
Sex: Female, Male
Sex: Female, Male(Participants)DBV712 250 μgPlaceboTotal
Female8949138
Male14969218
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DBV712 250 μgPlaceboTotal
White19496290
Black or African American123
Asian19827
Other241236
Screening Eliciting Dose (ED) Subgroup
Screening Eliciting Dose (ED) Subgroup(Participants)DBV712 250 μgPlaceboTotal
Screening ED Subgroup 1412061
Screening ED Subgroup 219798295
08

Study locations

31 sites
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • University of California, Rady Children's Hospital
    San Diego, California 92123, United States
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Boston Childrens' Hospital
    Boston, Massachusetts 02115, United States
  • Jaffe Food Allergy Institute
    New York, New York 10029, United States
  • The University of North Carolina - Chapell Hill
    Chapel Hill, North Carolina 27599, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Children's Medical Center of Dallas
    Dallas, Texas 75235, United States
  • Baylor College of Medicine - Texas Children's Hospital
    Houston, Texas 77030, United States
  • ASTHMA, Inc.
    Seattle, Washington 98115, United States
  • Allergy Medical
    Brisbane, Australia
  • Princess Margaret Hospital for Children
    Perth, Australia
  • Children's Hospital Westmead
    Sydney, Australia
  • British Columbia Children's Hospital
    Vancouver, British Columbia V5H 3V4, Canada
  • Cheema Research Inc.
    Mississauga, Ontario L5A 3V4, Canada
  • Ottawa Allergy Asthma Research Institute
    Ottawa, Ontario K1Y 4G2, Canada
  • Gordon Sussman Clinical Research Inc.
    Toronto, Ontario M4V 1R2, Canada
  • CHUM & CHU Sainte-Justine
    Montréal, Quebec H3T 1C4, Canada
  • Centre de Recherche Appliquée en Allergie de Québec (CRAAQ)
    Quebec, QC G1V4M6, Canada
  • Charité Universitätsmedizin Berlin
    Berlin, D-13353, Germany
  • St.-Marien-Hospital
    Bonn, D-53115, Germany
  • Universitätsklinikum Erlangen
    Erlangen, Germany
  • Clinical Investigations Unit
    Cork, Ireland
  • Our Lady's Children's Hospital
    Dublin, Ireland
09

References and documents

Publications

  • Fleischer DM, Greenhawt M, Sussman G, Begin P, Nowak-Wegrzyn A, Petroni D, Beyer K, Brown-Whitehorn T, Hebert J, Hourihane JO, Campbell DE, Leonard S, Chinthrajah RS, Pongracic JA, Jones SM, Lange L, Chong H, Green TD, Wood R, Cheema A, Prescott SL, Smith P, Yang W, Chan ES, Byrne A, Assa'ad A, Bird JA, Kim EH, Schneider L, Davis CM, Lanser BJ, Lambert R, Shreffler W. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. JAMA. 2019 Mar 12;321(10):946-955. doi: 10.1001/jama.2019.1113. PubMed 30794314 ↗
  • Greenhawt M, Kim EH, Campbell DE, Green TD, Lambert R, Fleischer DM. Improvements in eliciting dose across baseline sensitivities following 12 months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years. J Allergy Clin Immunol Pract. 2020 Oct;8(9):3219-3221. doi: 10.1016/j.jaip.2020.05.030. Epub 2020 Jun 2. No abstract available. PubMed 32502548 ↗
  • Remington BC, Campbell DE, Green TD, Fleischer DM, Koppelman SJ. Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results: Relevance for exposure through restaurant meals. Ann Allergy Asthma Immunol. 2021 Feb;126(2):208-209. doi: 10.1016/j.anai.2020.11.015. Epub 2020 Nov 28. No abstract available. PubMed 33259921 ↗
  • Remington BC, Krone T, Kim EH, Bird JA, Green TD, Lack G, Fleischer DM, Koppelman SJ. Estimated risk reduction to packaged food reactions by epicutaneous immunotherapy (EPIT) for peanut allergy. Ann Allergy Asthma Immunol. 2019 Nov;123(5):488-493.e2. doi: 10.1016/j.anai.2019.08.007. Epub 2019 Aug 20. PubMed 31442495 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2021, 4 years 1 month after primary completion. A results delay was requested in Feb 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2015
First posted
Dec 22, 2015
Start
Dec 2015
Primary completionActual
Aug 18, 2017
CompletionActual
Aug 18, 2017
Results delay requested
Feb 28, 2019
Results first posted
Oct 15, 2021
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02636699
Lead sponsor
DBV Technologies
Responsible party
Sponsor
First posted
Dec 22, 2015
Start date
Dec 2015
Primary completion
Aug 18, 2017
Completion
Aug 18, 2017
Results posted
Oct 15, 2021
Last update
Jun 18, 2025

Study contacts

David M Fleischer, MD
principal investigator · Children's Hospital Colorado

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palforzia

Start the discussion